Here's Why Arcutis Biotherapeutics, Inc. (ARQT) is a Great Momentum Stock to Buy

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Arcutis Biotherapeutics, Inc. (ARQT) - ARQT currently holds a Momentum Style Score of B, indicating potential as a solid momentum pick [3][12] - The company has a Zacks Rank of 2 (Buy), which is associated with a strong track record of outperformance [4][12] Performance Metrics - Over the past week, ARQT shares increased by 0.52%, while the Zacks Medical - Biomedical and Genetics industry remained flat [6] - In a longer timeframe, ARQT's monthly price change is 10.54%, significantly outperforming the industry's 0.92% [6] - Over the last quarter, ARQT shares rose by 25.73%, and over the past year, they increased by 90.11%, compared to the S&P 500's gains of 9.31% and 17.01%, respectively [7] Trading Volume - ARQT's average 20-day trading volume is 1,603,419 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, two earnings estimates for ARQT have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$0.55 to -$0.46 [10] - For the next fiscal year, two estimates have also moved upwards with no downward revisions [10]